3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Genitourinary
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
15
Lung Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Hematologic Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Lymphoma, Large-Cell, Anaplastic
2
Breast Neoplasms
2
Brain Neoplasms
2
Thyroid Neoplasms
1
Sexual Dysfunction, Physiological
1
Sarcoma
1
Rare Tumour
1
Rare Tumor
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Lymphoma
1
Glioblastoma
1
Genomic Instability
1
Gastrointestinal Neoplasms
1
Eunuchism
1
Erectile Dysfunction
1
Disease Resistance
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
Cyclophosphamide
4
Gemcitabine
3
isatuximab
2
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
anlotinib
2
alectinib
2
Vemurafenib
2
Sunitinib
2
Rituximab
2
Lenalidomide
2
Dexamethasone
2
Cisplatin
2
trametinib
1
spartalizumab
1
pomalidomide
1
pertuzumab
1
penpulimab
1
pembrolizumab
1
olaparib
1
niraparib
1
lutetium Lu 177 dotatate
1
ibritumomab tiuxetan
1
fludarabine
1
dabrafenib
1
copper dotatate CU-64
1
Trastuzumab
1
Taxes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms by Histologic Type
×
alectinib
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled